US Birth Rate Plunges to New Low — CDC
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The United States' total fertility rate fell to a record low in 2024, dipping below 1.6 children per woman, according to new federal data released Thursday by the Centers for Disease Control and Prevention (CDC). This marks a significant demographic milestone for a country that once stood apart among developed nations for maintaining a replacement-level birth rate of around 2.1 children per woman.
The U.S. fertility rate, once buoyed by post-World War II baby booms and comparatively high birth rates among younger women, has been steadily declining for nearly two decades. Many women are delaying motherhood or opting out of having children altogether — a trend now bringing American fertility rates closer to those of Western Europe. World Bank data confirms this alignment with long-standing European demographic patterns.
The toes of a baby are seen at a hospital in McAllen, Texas, on Wednesday, July 29, 2020.
The toes of a baby are seen at a hospital in McAllen, Texas, on Wednesday, July 29, 2020.
Associated Press
Despite concern in some political circles, experts suggest the falling birth rate reflects broader cultural and economic shifts, rather than an imminent population crisis. "We're seeing this as part of an ongoing process of fertility delay," said Leslie Root, a fertility and population policy researcher at the University of Colorado Boulder. "We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths."
Nevertheless, declining fertility has captured the attention of policymakers. In response to the trend, the Trump administration has advocated for several pro-natal measures, including an executive order aimed at expanding access to and reducing the cost of in vitro fertilization. The administration has also floated the idea of "baby bonuses" to incentivize family growth.
But critics argue that these proposals are unlikely to reverse the trend without addressing deeper structural issues. Karen Guzzo, director of the Carolina Population Center at the University of North Carolina, said many young people are simply not ready to start families due to financial uncertainty, lack of support systems, and late marriages. "Worry is not a good moment to have kids," she explained. "And that's why birth rates in most age groups are not improving."
Asked about the administration's initiatives, Guzzo was skeptical: "The things that they are doing are really symbolic and not likely to budge things for real Americans." She emphasized that lasting change would require more comprehensive policies, such as paid parental leave and affordable child care.
The CDC's updated figures for 2024 show that the total fertility rate dropped from 1.621 in 2023 to 1.599. That statistic is derived from a more detailed analysis of birth certificates and replaced earlier provisional estimates.
Interestingly, the new report also shows a 1% increase in overall births — roughly 33,000 more babies — compared to 2023, bringing the total to just over 3.6 million. However, this does not reflect a higher birth rate. The CDC clarified that the discrepancy stemmed from recalculated population estimates, which now account for an increase in women of childbearing age due to immigration.
"That's plausible," Root said. "As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups."
Ultimately, both experts agree the U.S. faces a complex demographic shift shaped by economics, policy, and evolving personal choices.
This article includes reporting by the Associated Press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Coke with cane sugar may not be that big of a MAHA victory
Coca-Cola is going to offer a cane sugar version of its signature beverage, rather than one sweetened with corn syrup. Major segments of the food industry, including General Mills and Heinz, have pledged to remove certain colored dyes from their products. The fast-food chain Steak 'n Shake is making french fries in beef tallow rather than vegetable oil. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has claimed them all as significant victories for his 'make America healthy again' (MAHA) movement as part of its quest to reform the U.S. food supply. 'Froot Loops is finally following its nose — toward common sense,' Kennedy said on social platform X after cereal-maker WK Kellogg Co. agreed to remove synthetic dyes from its cereal by 2027. 'I urge more companies to step up and join the movement to Make America Healthy Again.' But nutrition and food policy experts say the moves are a far cry from actually making America healthier. While they praised the administration and MAHA for drawing attention to what they said is a broken food system, the victories touted thus far have been largely symbolic and rely on the goodwill of an industry that is eager to appear helpful to avoid strict government regulation. 'I think if we're really curious about improving public health, some of the small health initiatives, like … replacing high fructose corn syrup with cane sugar, are really not where the administration should be channeling their efforts and leveraging the power that they do have,' said Priya Fielding-Singh, director of policy and programs at the George Washington University Global Food Institute. 'I think they should be focusing their efforts on initiatives that actually address the root of the problem, which is essentially a food system that promotes excess sugar, salt and fat,' Fielding-Singh said. Health officials and GOP lawmakers have taken to conservative media in recent weeks to tout the commitments from food and beverage companies to remove synthetic dyes. According to the HHS, nearly 35 percent of the industry has made such a commitment. But there's been no force behind the companies' actions, which experts said is an issue. 'Simply switching from synthetic to natural colors will not make these products less likely to cause obesity,' said Jerold Mande, a former senior official during three administrations at the Food and Drug Administration (FDA), the Department of Agriculture and the Occupational Safety and Health Administration. Barry Popkin, a nutrition professor at the University of North Carolina Gillings School of Global Public Health, said Kennedy could make a major statement by banning all colors and dyes. It wouldn't directly make Americans healthy, but it would go a long way toward making ultra-processed food look less appealing. 'All this voluntary stuff only goes so far. It really does minimal impact,' Popkin said. 'Unless he goes to the FDA and has the FDA change a regulation … there's nothing.' Kennedy has also singled out the use of high-fructose corn syrup as a major contributor to diabetes and obesity. He has previously called it 'poison,' an epithet he repeated in late April when talking about sugar. When Steak 'n Shake said earlier this month it was going to sell Coca-Cola with real cane sugar, Kennedy praised the move. 'MAHA is winning,' Kennedy posted on X. But experts said there's no substantial difference in the benefits of using cane sugar as a substitute for high-fructose corn syrup. 'At the end of the day, a Coke is still a can of Coke. It's not a fruit or a vegetable, right? And so if you're not shifting consumption away from these higher calorie, lower nutrient processed foods, toward nutrient dense, health promoting foods, then you're not actually going to be shifting the health of Americans in the right direction,' Fielding-Singh said. But if Kennedy thinks sugar is poison, 'they're both sugar and would both be poison, in his words,' said Mande, who is now CEO of Nourish Science. Health officials argue industry cooperation is key to the MAHA agenda. 'Working with industry is the best place to start. And we believe in industry to do the right thing when called upon,' Food and Drug Administration Commissioner Marty Makary and Centers for Medicare and Medicaid Services Administrator Mehmet Oz wrote in a joint op-ed in The Wall Street Journal. 'Our agencies are in a strong position to show Americans which companies are doing the right thing when it comes to popular reforms. By the time we're done, we will have built new relationships and be better positioned to hold them accountable,' Makary and Oz wrote. Yet there is plenty the agency can, and should do, that industry has pushed back against. Aviva Musicus, science director of the nonprofit Center for Science in the Public Interest, said MAHA is wasting its political capital. 'It's striking that we haven't seen the administration use policy to improve the food system. It's solely relying on voluntary industry commitments that we've seen repeatedly fail in the past,' Musicus said. 'In pushing the food industry to change, Trump and RFK Jr. have a chance to live up to their promises to fight chronic disease. Coca-Cola is at the table, but they're wasting the opportunity to actually improve health. The administration should focus on less sugar, not different sugar,' Musicus added. Popkin said he would like to see warning labels on ultra-processed foods high in sodium, added sugar and saturated fat. Kennedy 'hasn't tackled ultra-processed food yet. That'll be where he could make an impact on health in the U.S. and all the non-communicable diseases, including obesity. But he hasn't gone there yet,' Popkin said. The coming months will reveal more on the MAHA movement's plans to change how Americans eat. New dietary guidelines will be released 'in the next several months,' Kennedy said recently. In addition, a second MAHA report focused on policy recommendations is expected in August. 'We have to be considering that there could be real potential down the road,' Popkin said. 'But [there's been] nothing yet. That document will tell us if there ever be.'
The Hill
an hour ago
- The Hill
The FDA must crack down on dangerous knockoff weight-loss drugs
For the first time, there is real hope in the fight against obesity. New data from the Centers for Disease Control and Prevention's National Center for Health Statistics shows that adult obesity rates in the U.S. may finally be flatlining after annual increases since at least 2011. Obesity has long been understood to be the second leading cause of preventable death in America. Neither negative cultural attitudes about weight nor government messaging campaigns about diets have helped curb it. Yet like most insurmountable problems, we are innovating our way out of it. Experts believe a significant part of recent progress is due to powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs. But just as these drugs are changing lives, a dangerous shadow market is growing alongside them. Compounded versions, which are copies of the original drugs made in smaller pharmacies, are flooding websites, med spas and clinics. These versions are often cheaper and easier to get than the real thing. They are also frequently untested, poorly regulated and, in many cases, illegal. The FDA has received more than 500 reports of serious side effects tied to compounded semaglutide and tirzepatide, the active ingredients in Ozempic and Mounjaro. Some patients have landed in the hospital after taking the wrong dose. That is not surprising when you consider that many of these vials come without proper labels or instructions. In 2023 alone, poison control centers received nearly 3,000 semaglutide-related calls, a huge jump from previous years. Many of those cases involved compounded or mislabeled versions of the medication. There are also serious concerns about what is actually in these products. The FDA has warned that some pharmacies are using different chemical forms of semaglutide, called salt forms, that are not approved for use and may not be safe. In April 2025, the agency seized counterfeit Ozempic from the U.S. supply chain after discovering that some vials contained the wrong ingredients or were contaminated with dangerous bacteria. These are not technical violations. They are real risks to people's health. During earlier shortages, compounding was allowed under special circumstances. But those shortages have ended, and the FDA has ordered most pharmacies to stop making these versions. Despite that, many continue to operate in legal gray zones or offer these drugs online. The harm does not stop with safety concerns. This trend also threatens future breakthroughs in obesity care. Companies like Novo Nordisk and Eli Lilly spent years and billions of dollars to develop these treatments. Now, they and others are working on new and even more effective drugs. When unapproved copies flood the market, it becomes harder to fund innovation. If investors cannot count on fair returns, the next generation of such medications may not make it out of the lab. Perhaps the biggest risk is to public trust. When someone has a bad experience with a fake or contaminated version, they may begin to doubt all weight loss innovations. That fear can ripple through the health system, making insurers and doctors more hesitant to support treatments that are helping with the genuine public health emergency of obesity. None of this means that compounding should disappear. It has a place when patients have specific medical needs that cannot be met by the approved versions, such as allergies or special dosing requirements. But what is happening now is not about rare exceptions. The FDA should continue cracking down on compounders that use unapproved ingredients or sell mislabeled products disguised as 'research chemicals.' At the same time, insurers and lawmakers need to make the real thing more affordable by removing middlemen such as pharmacy benefit managers. No one should have to choose between risking their health and going broke. We are finally making progress against a disease that affects nearly half the country and has stumped policymakers and advocates for decades. But progress is fragile. Unregulated versions of GLP-1s cannot be allowed to dominate the market. We risk undoing the progress reported by the CDC in the fight against obesity, and if we get this right, the trend could be reversed. That means longer lives for more people, lived in dignity and to the fullest.
Yahoo
2 hours ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
